Review of non-clinical risk models to aid prevention of breast cancer

被引:0
|
作者
Kawthar Al-Ajmi
Artitaya Lophatananon
Martin Yuille
William Ollier
Kenneth R. Muir
机构
[1] The University of Manchester,Division of Population Health, Health Services Research and Primary Care, Faculty of Biology, Medicine and Health, Centre for Epidemiology
来源
Cancer Causes & Control | 2018年 / 29卷
关键词
Assessment risk tool; Calibration; Discrimination; Risk factors; Risk prediction; Concordance and E/O statistics;
D O I
暂无
中图分类号
学科分类号
摘要
A disease risk model is a statistical method which assesses the probability that an individual will develop one or more diseases within a stated period of time. Such models take into account the presence or absence of specific epidemiological risk factors associated with the disease and thereby potentially identify individuals at higher risk. Such models are currently used clinically to identify people at higher risk, including identifying women who are at increased risk of developing breast cancer. Many genetic and non-genetic breast cancer risk models have been developed previously. We have evaluated existing non-genetic/non-clinical models for breast cancer that incorporate modifiable risk factors. This review focuses on risk models that can be used by women themselves in the community in the absence of clinical risk factors characterization. The inclusion of modifiable factors in these models means that they can be used to improve primary prevention and health education pertinent for breast cancer. Literature searches were conducted using PubMed, ScienceDirect and the Cochrane Database of Systematic Reviews. Fourteen studies were eligible for review with sample sizes ranging from 654 to 248,407 participants. All models reviewed had acceptable calibration measures, with expected/observed (E/O) ratios ranging from 0.79 to 1.17. However, discrimination measures were variable across studies with concordance statistics (C-statistics) ranging from 0.56 to 0.89. We conclude that breast cancer risk models that include modifiable risk factors have been well calibrated but have less ability to discriminate. The latter may be a consequence of the omission of some significant risk factors in the models or from applying models to studies with limited sample sizes. More importantly, external validation is missing for most of the models. Generalization across models is also problematic as some variables may not be considered applicable to some populations and each model performance is conditioned by particular population characteristics. In conclusion, it is clear that there is still a need to develop a more reliable model for estimating breast cancer risk which has a good calibration, ability to accurately discriminate high risk and with better generalizability across populations.
引用
收藏
页码:967 / 986
页数:19
相关论文
共 50 条
  • [1] Review of non-clinical risk models to aid prevention of breast cancer
    Al-Ajmi, Kawthar
    Lophatananon, Artitaya
    Yuille, Martin
    Ollier, William
    Muir, Kenneth R.
    CANCER CAUSES & CONTROL, 2018, 29 (10) : 967 - 986
  • [2] Polysaccharides with Antitumor Effect in Breast Cancer: A Systematic Review of Non-Clinical Studies
    Corso, Claudia Rita
    Mulinari Turin de Oliveira, Natalia
    Moura Cordeiro, Leonardo
    Sauruk da Silva, Karien
    da Silva Soczek, Suzany Hellen
    Frota Rossato, Virgilio
    Fernandes, Elizabeth Soares
    Maria-Ferreira, Daniele
    NUTRIENTS, 2021, 13 (06)
  • [3] Non-clinical Models to Determine Drug Passage into Human Breast Milk
    Ventrella, Domenico
    Forni, Monica
    Bacci, Maria Laura
    Annaert, Pieter
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (05) : 534 - 548
  • [4] Intrathecal dosing methods in non-clinical models: A review of emerging practices
    Sparapani, Samantha
    Bujold, Kim
    Maghezzi, Said
    Galicia, Archival
    Bennamoune, Nehla
    Foret, Morgan K.
    Authier, Simon
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2023, 123
  • [5] Non-clinical Drivers of Variation in Preoperative MRI Utilization for Breast Cancer
    Linda M. Pak
    Amanda Banaag
    Tracey P. Koehlmoos
    Louis L. Nguyen
    Peter A. Learn
    Annals of Surgical Oncology, 2020, 27 : 3414 - 3423
  • [6] Non-clinical Drivers of Variation in Preoperative MRI Utilization for Breast Cancer
    Pak, Linda M.
    Banaag, Amanda
    Koehlmoos, Tracey P.
    Nguyen, Louis L.
    Learn, Peter A.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (09) : 3414 - 3423
  • [7] Non-clinical drivers of variation in preoperative MRI utilization for breast cancer
    Pak, L. M.
    Banaag, A.
    Koehlmoos, T. P.
    Haider, A. H.
    Learn, P. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [8] Clinical risk prediction models for breast cancer: A review of models developed between 2010 and 2018
    Siesling, S.
    Hueting, T.
    Tip, B.
    Mentink, R.
    Koffijberg, E.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] IMMUNOTHERAPY OF NON-CLINICAL VAGINAL CANCER
    GUTHRIE, D
    WAY, S
    LANCET, 1975, 2 (7947): : 1242 - 1243
  • [10] 4-Nitrochalcone as a potential drug in non-clinical breast cancer studies
    Galindo, Claudia Martins
    Milani, Leticia
    de Lima, Lucas Trevisan Franca
    Adami, Eliana Rezende
    Go, Simei
    de Noronha, Lucia
    Beltrame, Olair Carlos
    Klassen, Giseli
    Ramos, Edneia Amancio de Souza
    Elferink, Ronald P. J. Oude
    Acco, Alexandra
    CHEMICO-BIOLOGICAL INTERACTIONS, 2024, 387